From: Exercise training in childhood-onset systemic lupus erythematosus: a controlled randomized trial
Variable | C-SLE trained (n= 10) | C-SLE non-trained (n= 9) | Control (n= 10) |
---|---|---|---|
Age, years | 12.9 (2.3) | 13.0 (1.8) | 12.0 (1.8) |
Body weight, Kg | 48.7 (10.1) | 49.7 (12.1) | 46.6 (14.5) |
Height, m | 1.48 (0.09) | 1.44 (0.11) | 1.51 (0.13) |
Body mass index, Kg/m2 | 22.3 (3.8) | 23.9 (3.4) | 21.2 (1.7) |
Pubertal stages I/II/III/IV/V, number of individuals | 1/2/2/2/3 | 0/2/3/2/2 | 3/2/1/2/2 |
SLEDAI-2K, score | 5.3 (5.3) | 5.6 (6.4) | NA |
SLICC/ACR-DI, score | 0.4 (0.7) | 0.4 (0.7) | NA |
Disease duration, years | 3.3 (2.6) | 4.3 (2.6) | NA |
Current dose of prednisone, mg/d | 19.8 (17.0) | 15.5 (7.7) | NA |
Cumulative dose of prednisone, g | 13.7 (6.7) | 20.9 (13.0) | NA |
Current dose of azathioprine, mg/d | 128.6 (39.3) | 121.4 (17.2) | NA |
Cumulative dose of azathioprine, g | 58.2 (32.1) | 62.2 (41.1) | NA |
Current dose of chloroquine, g/d | 205.8 (51.2) | 205.6 (51.2) | NA |
Cumulative dose of chloroquine, g | 129.7 (119.9) | 181.3 (121.5) | NA |
Drugs, number of patients (%) | |||
Prednisone | 10 (100) | 9 (100) | |
Fluoxetine | 1 (10) | 0 (0) | NA |
Diltiazen | 1 (10) | 0 (0) | NA |
Enalapril | 3 (30) | 5 (55) | NA |
Losartan | 1 (10) | 1 (11) | NA |
Anlodipine | 0 (0) | 2 (22) | NA |
Carbamazepine | 1 (10) | 0 (0) | NA |
Methylphenidate | 0 (0) | 0 (0) | NA |
Clopidogrel | 0 (0) | 0(0) | NA |
Warfarin | 1(10) | 0(0) | NA |
Acetylsalicylic Acid | 1 (10) | 0 (0) | NA |